Literature DB >> 21175738

Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain.

R D Jolly1, N R Marshall, M R Perrott, K E Dittmer, K M Hemsley, H Beard.   

Abstract

AIMS: The research concerns enzyme replacement therapy in lysosomal storage diseases with central nervous system involvement. The principle aim was to understand the routes of entry of enzyme into the brain when delivered directly into the cerebrospinal fluid (CSF) via the cerebellomedullary cistern.
METHODS: Pathways for absorption of replacement enzyme were investigated in dogs with mucopolysaccharidosis IIIA (MPSIIIA) following intracisternal injections of human recombinant N-sulphoglucosamine sulphohydrolase (rhSGSH, EC3.10.1.1) by light and confocal microscopy using chromogenic and fluorescent immune probes.
RESULTS: Enzyme entered the brain superficially by penetration of the pia/glia limitans interface, but the main route was perivascular along large veins, arteries and arterioles extending onto capillaries. It further dispersed into surrounding neuropil to be taken up by neurones, macrophages, astrocytes and oligodendroglia. Enzyme also entered the lateral ventricles adjacent to the choroid plexus, probably also by the tela choroidea and medullary velum, with further spread throughout the ventricular system and spinal canal. There was secondary spread back across the ependyma into nervous tissue of brain and spinal cord.
CONCLUSIONS: Enzyme mainly enters the brain by a perivascular route involving both arteries and veins with subsequent spread within the neuropil from where it is taken up by a proportion of neurones and other cells. Penetration of enzyme through the pia/glia limitans is minor and superficial.
© 2011 The Authors. Neuropathology and Applied Neurobiology © 2011 British Neuropathological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21175738     DOI: 10.1111/j.1365-2990.2010.01158.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  9 in total

Review 1.  Physiology of the intrathecal bolus: the leptomeningeal route for macromolecule and particle delivery to CNS.

Authors:  Mikhail I Papisov; Vasily V Belov; Kimberley S Gannon
Journal:  Mol Pharm       Date:  2013-02-12       Impact factor: 4.939

Review 2.  Blood-brain barrier structure and function and the challenges for CNS drug delivery.

Authors:  N Joan Abbott
Journal:  J Inherit Metab Dis       Date:  2013-04-23       Impact factor: 4.982

3.  Merits of combination cortical, subcortical, and cerebellar injections for the treatment of Niemann-Pick disease type A.

Authors:  Jie Bu; Karen M Ashe; John Bringas; John Marshall; James C Dodge; Mario A Cabrera-Salazar; John Forsayeth; Edward H Schuchman; Krystof S Bankiewicz; Seng H Cheng; Lamya S Shihabuddin; Marco A Passini
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

4.  Evaluation of enzyme dose and dose-frequency in ameliorating substrate accumulation in MPS IIIA Huntaway dog brain.

Authors:  Barbara King; Neil Marshall; Helen Beard; Sofia Hassiotis; Paul J Trim; Marten F Snel; Tina Rozaklis; Robert D Jolly; John J Hopwood; Kim M Hemsley
Journal:  J Inherit Metab Dis       Date:  2014-11-25       Impact factor: 4.982

5.  Intrathecal antibody distribution in the rat brain: surface diffusion, perivascular transport and osmotic enhancement of delivery.

Authors:  Michelle E Pizzo; Daniel J Wolak; Niyanta N Kumar; Eric Brunette; Christina L Brunnquell; Melanie-Jane Hannocks; N Joan Abbott; M Elizabeth Meyerand; Lydia Sorokin; Danica B Stanimirovic; Robert G Thorne
Journal:  J Physiol       Date:  2017-12-18       Impact factor: 5.182

6.  The effects of intracisternal enzyme replacement versus sham treatment on central neuropathology in preclinical canine fucosidosis.

Authors:  Gauthami Sudhamayee Kondagari; Jessica Louise Fletcher; Rachel Cruz; Peter Williamson; John J Hopwood; Rosanne Maree Taylor
Journal:  Orphanet J Rare Dis       Date:  2015-11-04       Impact factor: 4.123

7.  Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells.

Authors:  Ruben J Boado; Jeff Zhiqiang Lu; Eric Ka-Wai Hui; William M Pardridge
Journal:  Mol Pharm       Date:  2014-06-26       Impact factor: 4.939

8.  Pharmacokinetic Modeling of Intrathecally Administered Recombinant Human Arylsulfatase A (TAK-611) in Children With Metachromatic Leukodystrophy.

Authors:  Steven Troy; Margaret Wasilewski; Jack Beusmans; C J Godfrey
Journal:  Clin Pharmacol Ther       Date:  2020-02-25       Impact factor: 6.875

Review 9.  The glymphatic hypothesis: the theory and the evidence.

Authors:  Stephen B Hladky; Margery A Barrand
Journal:  Fluids Barriers CNS       Date:  2022-02-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.